Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02020824
Other study ID # CTRLSTRESS
Secondary ID 2013-A01280-45 I
Status Recruiting
Phase N/A
First received December 19, 2013
Last updated October 29, 2015
Start date April 2014
Est. completion date July 2017

Study information

Verified date October 2015
Source Qualissima
Contact Eric MALBOS, MD
Phone 0491746287
Email eric.malbos@ap-hm.fr
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

Virtual reality is currently used as a therapeutic strategy in common phobia as agoraphobia or acrophobia, since it permits to have a better control (on occurrence of events or on the environment) during the therapy than in "in vivo" therapy. Our hypothesis here is that we can improves the therapeutic effects of the virtual exposure by giving control to acrophobic patients during their exposure.


Description:

The study is based on the exposure of acrophobic patients to virtual environments. During the study, several groups of patients will be distributed according to different conditions: exposure to anxiogenous virtual environments and exposure with the ability to control and secure the anxiogenous virtual environments.

The interest of this project is to improve therapy by exposure to virtual reality. Our project offers a systematic therapeutic approach (using virtual reality and the concept of control) where current therapy are too often approximate. We aim to demonstrate the effectiveness of the control of virtual environments on symptomatic and psychophysiological levels, to evaluate the adoption of these methods in the couple patients-caregivers and also to understand the brain mechanisms (including those prefrontal) involved in this therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date July 2017
Est. primary completion date June 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria of all subjects:

- 18 to 60 years old

- Male or female

- All subjects will be fluent in French.

- Fully informed and freely given, signed Informed consent in written form.

- Patient / Subject affiliated or beneficiary of a social/health security insurance.

Inclusion criteria for acrophobic patients:

- Patients not hospitalized suffering from acrophobia (according to DSM-IV, APA 2000).

- Patients receiving pharmacotherapy (anxiolytics, hypnotics, etc.) may be included provided they are stabilized on treatment for at least 8 weeks.

- Score inferior to 6 at the Behavioural Avoidance Test

Inclusion criteria for healthy volunteers:

- People not hospitalized showing no sign of acrophobia.

- Score superior or equal to 10 at the Behavioural Avoidance Test.

Exclusion Criteria for all subjects:

- Pregnant woman (urine and blood ß -HCG test) or lactating (contraindication to PET-scan).

- Women of childbearing potential without effective contraception (contraindication to PET-scan).

- Subject participating in another research evaluating other treatments including a period of exclusion still ongoing.

- Persons under guardianship and adults subject submitted to a measure of legal protection or unable to consent.

- Persons deprived of their liberty by a judicial or administrative decision, those hospitalized without consent under Articles L. 3212-1 and L. 3213-1 that do not fall under the provisions of Article L. 1121-8 and admitted to a health or social institution for purposes other than research.

- People with a non-stabilized diabetes (contraindication to PET-scan).

- Addictions to alcohol or drugs.

- Persons suffering from claustrophobia.

- Contraindications to fMRI.

- People with hearing loss.

- Strong visual impairment (> 5 diopters) not corrected by contact lenses.

Exclusion criteria for acrophobic patients:

- Patients continuing psychotherapy.

- Patients suffering from other neurological disorders or comorbid psychiatric diseases than acrophobia.

- Patients suffering from severe organic disorders that could disable or disrupt the therapeutic process.

- The concomitant drugs at inclusion should not be modified or discontinued during the study.

- No psychotherapy should be initiated during the study.

Exclusion criteria for healthy volunteers:

- Subjects with a known psychiatric or neurological disorders, diagnosed for depression, with emotional disorders affecting their perception of the environment, or taking a medication that may affect the auditory and visual perception, concentration or emotions.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Exposure to anxiogenous environments
The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms "Exposure to anxiogenous environments (with or without control)".
Other:
Imagery with functional MRI initial
Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
Imagery with PET-scanner initial
Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
Imagery with functional MRI final
Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
Imagery with PET-scanner final
Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.

Locations

Country Name City State
France Service hospitalo-universitaire de psychologie médicale de psychiatrie d'adultes du Pr Lançon - CHU Marseille Marseille

Sponsors (2)

Lead Sponsor Collaborator
Qualissima France: Centre National de la Recherche Scientifique

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Behavioural Avoidance Test (BAT) Objective measure of behavior scored on 10 points in response to a virtual environment representing a situation feared by acrophobic patients. This virtual environment is a flat landscape with a platform overlooking a canyon of 800 meters. 1 year (4 times) No
Secondary Brain activity (functional MRI) Anatomical and functional : brain activity in several cortical and subcortical areas with fMRI (BOLD signal intensity) 12 weeks (2 times) No
Secondary Synaptic activity (PET-scan) Metabolic and functional : synaptic activity with PET scanner 12 weeks (2 times) No
Secondary Cognitive measurements Attentional bias (DOT test) 12 weeks (2 times) No
Secondary Cognitive measurements Emotional valence (emotional congruence task) 12 weeks (2 times) No
Secondary Cognitive measurements Questionnaire on acrophobia (AQ: Acrophobia Questionnaire) 1 year (4 times) No
Secondary Cognitive measurements Questionnaire on acrophobia (ATHQ: Attitude Towards Heights Questionnaire) 1 year (4 times) No
Secondary Cognitive measurements Questionnaire on anxiety (STAI: Spielberger Trait Anxiety Inventory) 1 year (4 times) No
Secondary Cognitive measurements Questionnaire on depression (BDI: Beck Depression Inventory) 1 year (4 times) No
Secondary Quality of life Quality of Life (SF-12: Medical Outcome Study Short Form) 1 year (4 times) No
Secondary Cognitive measurements During the 8 sessions of exposure to virtual reality: Questionnaires on anxiety (SUD: Subjective Unit of Discomfort) 10 weeks (8 times) No
Secondary Cognitive measurements During the 8 sessions of exposure to virtual reality: Progression recorded and time to progression from one environment to another during sessions (number of environments completed, time of execution, others ..) 10 weeks (8 times) No
Secondary Ergonomy During the 8 sessions of exposure to virtual reality: Questionnaire on the applicability / realism / ergonomy (PQ: Questionnaire on the state of Presence). 10 weeks (8 times) No
Secondary Psychophysiological During the 8 sessions of exposure to virtual reality: Psychophysiological objective measurements during exposure to virtual reality (electrodermal activity, electrocardiography, breathing rate) 10 weeks (8 times) No
Secondary Adverse events Assessment and description of all the occurrence of adverse events during the study. 1 year Yes
See also
  Status Clinical Trial Phase
Completed NCT01963806 - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder N/A
Completed NCT00121069 - Study of Escitalopram in the Treatment of Specific Phobia Phase 2/Phase 3
Recruiting NCT03653923 - Neurophysiological Correlates of Exposition Therapy in Spider Phobia N/A
Completed NCT00184106 - RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Phase 4
Completed NCT00051220 - Treatment for Specific Phobias in Children Phase 1/Phase 2
Completed NCT02387047 - Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly N/A
Completed NCT02310152 - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE) N/A
Completed NCT00000370 - Treatment of Social Phobia N/A
Completed NCT03012035 - The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants N/A
Completed NCT02007694 - Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Phase 2/Phase 3
Active, not recruiting NCT03188575 - Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT N/A
Completed NCT02432703 - A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder Phase 2
Terminated NCT01574014 - Glucocorticoid Treatment for Social Phobia Phase 2
Completed NCT00734422 - Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Phase 2/Phase 3
Not yet recruiting NCT02336802 - Threat-Avoidance Learning in Anxiety Patients N/A
Completed NCT01361074 - In Vivo Versus Augmented Reality Exposure for Small Animal Phobia N/A
Completed NCT00104195 - A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions Phase 1
Completed NCT00035412 - St. John's Wort Versus Placebo in Social Phobia Phase 2
Completed NCT00128401 - Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia Phase 2
Terminated NCT01623583 - Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Phase 4